A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Condition: Primary Mediastinal Large B Cell Lymphoma
MeSH terms: Lymphoma; Lymphoma, B-Cell
Intervention: Brentuximab Vedotin
Intervention description: Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
Intervention MeSH terms: Brentuximab Vedotin
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 15.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: PMLBCL; Brentuximab Vedotin; CD30-positive; Mediastinal Lymphoma

Summary:

      Study Objectives Primary:

      • To determine the antitumor efficacy of single-agent Brentuximab vedotin (1.8 mg/kg
      administered intravenously every 3 weeks) as measured by the overall objective response rate
      in patients with relapsed or refractory primary mediastinal large B-cell lymphoma.

      Secondary:

        -  To assess duration of tumor control, including duration of response and progression-free
           survival

        -  To assess survival

        -  To assess the safety and tolerability of Brentuximab vedotin

      Additional:

      • To assess disease-related symptoms

      Number of Planned Patients 20 patients will be enrolled in this study. Duration of the study
      The study duration is 18 months for enrollment and 2 years for the follow-up.
    

Eligibility criteria:

        Inclusion Criteria:

        Patients must meet all of the following inclusion criteria to be eligible for this study:

          1. Patients with relapsed or refractory PMLBCL who have previously received at least 1
             line of treatment. Patients must have completed any prior treatment with radiation,
             chemotherapy, biologics, immunotherapy and/or other investigational agents at least 4
             weeks prior to the first dose of Brentuximab vedotin.

          2. Histologically-confirmed CD30-positive disease.

          3. Age greater than or equal to 18 years.

          4. Fluorodeoxyglucose (FDG)-avid and measurable disease of at least 1.5 cm as documented
             by both PET and spiral CT.

          5. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          6. The following required baseline laboratory data: absolute neutrophil count (ANC)
             ≥1500/μL, unless known marrow involvement due to disease, platelets ≥75,000/μL, unless
             known marrow involvement due to disease, bilirubin ≤1.5X upper limit of normal (ULN)
             or ≤3X ULN for patients with Gilbert's disease, serum creatinine ≤1.5X ULN, alanine
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5X ULN.

          7. Serum Albumin ≥3 gr/dL;

          8. Females of childbearing potential must have a negative serum or urine β-hCG pregnancy
             test result within 7 days prior to the first dose of Brentuximab vedotin. Females of
             non-childbearing potential are those who are postmenopausal greater than 1 year or who
             have had a bilateral tubal ligation or hysterectomy.

          9. Both females of childbearing potential and males who have partners of childbearing
             potential must agree to use two effective contraceptive methods during the study and
             for 30 days following the last dose of study drug.

         10. Male patients, even if surgically sterilized (i.e., post vasectomy), who:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 6 months after the last dose of the study drug, or

               -  Agree to completely abstain from heterosexual intercourse

         11. Patients or their legally authorized representative must provide written informed
             consent.

        Exclusion Criteria:

          1. Previous treatment with Brentuximab vedotin.

          2. Previously received an allogeneic transplant.

          3. Congestive heart failure, Class III or IV, by the NYHA criteria.

          4. History of another primary malignancy for at least 3 years. (The following are exempt
             from the 3-year limit: nonmelanoma skin cancer, curatively treated localized prostate
             cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion
             on PAP smear.)

          5. Known cerebral/meningeal disease.

          6. Signs or symptoms of progressive multifocal leukoencephalopathy (PML).

          7. Pre-existing Peripheral Neuropathy ≥ 2;

          8. Any active systemic viral, bacterial, or fungal infection requiring treatment with
             antimicrobial therapy within 2 weeks prior to the first dose of Brentuximab vedotin.

          9. Current therapy with other systemic anti-neoplastic or investigational agents.

         10. Therapy with corticosteroids at greater than or equal to 20 mg/day prednisone
             equivalent within 1 week prior to the first dose of Brentuximab vedotin.

         11. Women who are pregnant or lactating and breastfeeding.

         12. Patients with a known hypersensitivity to recombinant proteins, murine proteins, or
             any excipient contained in the drug formulation.

         13. Known human immunodeficiency virus (HIV) positive.

         14. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
             infection.

         15. Patients with dementia or an altered mental state that would preclude the
             understanding and rendering of informed consent.